Stand Up To Cancer unveils latest gastroesophageal cancer research teams and awards

Stand Up To Cancer^® (SU2C) today announced three Research Teams focused on bringing latest therapies to clinical trials for the treatment of gastroesophageal cancer (GEC). The Research Teams, a component of a Dream Team Collective supported by the Torrey Coast Foundation, will unite top researchers from 11 institutions to handle critical problems in GEC prevention, diagnosis and treatment. The Dream Team Collective goals to foster latest and inclusive cancer research on the causes and coverings of GEC, mentor a brand new generation of scientists focused on GEC, bring latest treatments to the clinic, and supply medical professionals with tools and materials to higher advocate for GEC screening and treatment with their patients.

SU2C also funded three 2023 Phillip A. Sharp Innovation in Collaboration Awards – which give attention to bringing latest perspectives together and encourage the inclusion of early-career investigators – and one SU2C Maverick Early Profession Scientist Award – which is awarded to an investigator early of their profession and supports a cutting-edge concept that has great potential to affect patient care. Considered one of the Phillip A. Sharp Awards includes the Ziskin Prize, which honors legendary Hollywood producer and SU2C co-founder Laura Ziskin, who passed from breast cancer in 2011.

SU2C is always looking for out probably the most promising research opportunities to support our effort to bring latest and impactful cancer treatments to patients quickly. I’m enthusiastic about each of those latest grants as they push critical studies forward and can greatly expand our understanding of cancer – specifically subtypes which are tougher to treat.”

Julian Adams, Ph.D., SU2C’s chief science officer

The SU2C-Torrey Coast Foundation Gastroesophageal Cancer Dream Team Collective includes:

• Targeting Immune Evasion in Gastroesophageal Cancer – This team will give attention to finding higher treatment strategies for as much as 70% of gastroesophageal cancer (GEC) patients for whom current treatments don’t work. Led by Yelena Janjigian, M.D., chief of the gastrointestinal oncology service at Memorial Sloan Kettering Cancer Center, and co-led by Jedd Wolchok, M.D., Ph.D., the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, the team will investigate how GEC evades or suppresses the immune system. Focusing specifically on GEC that’s characterised by chromosomal instability, which is related to worse outcomes, metastasis and a resistance to current therapies, the team hopes to pinpoint drugs – or drug mixtures – that may higher treat GEC.
• Novel Therapeutic Approaches for Esophageal Squamous Cell Carcinoma – This team will give attention to creating latest therapeutic approaches for esophageal squamous cell carcinoma (ESCC). Led by Anil K. Rustgi, M.D., director on the Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center, and co-led by Kwok-Kin Wong, M.D., Ph.D., director of the Division of Hematology and Medical Oncology at NYU Langone’s Perlmutter Cancer Center, the team will investigate features of the local environment inside and surrounding ESCC where it occurs within the body – including ESCC metastasis – to propose genetic characteristics that might potentially be targeted with latest cancer therapies.
• Therapeutics for Gastroesophageal Adenocarcinoma: Application, Translation and Discovery – This team will give attention to uncovering latest therapies for gastroesophageal adenocarcinoma. Led by William Sellers, M.D., core institute member at Broad Institute of MIT and Harvard, and co-led by Marcela Maus, M.D., Ph.D., director of cellular immunotherapy at Massachusetts General Hospital’s Cancer Center, the team plans to define and goal the cell surface of gastroesophageal adenocarcinoma and squamous cell carcinoma through a greater understanding of the molecular makeup of those cancers. The team also plans to develop CAR-T cells – an immunotherapy that utilizes a patient’s own modified immune cells to fight cancer – for certain forms of gastric and esophageal cancers.

The Phillip A. Sharp Awards are:

• The Phillip A. Sharp – Laura Ziskin Innovation in Collaboration Award: Development of microfluidic blood exchange as a next-generation parabiosis for tumor/microbiota immunology – This team will pair immunology with bioengineering to construct upon current research that shows microbes residing throughout the human gut communicate with the immune system to enable anti-tumor responses to cancers. The team, led by Rabi Upadhyay, M.D., assistant professor at NYU Grossman School of Medicine and co-led by Scott Manalis, Ph.D., the David H. Koch professor in engineering at Massachusetts Institute of Technology, hopes to uncover ways through which gut microbes could possibly be used together with other treatment strategies for future cancer therapies.

• The Phillip A. Sharp Innovation in Collaboration Award: Therapeutic biparatopic antibodies targeting FGFR2 in gastric cancer – This team will work to discover higher treatments for the 30% of gastric cancer patients through which a certain protein called FGFR2 is overexpressed, which results in lower survival rates. Led by Sandra Ryeom, Ph.D., associate professor at Columbia University and co-led by William Sellers, M.D., core institute member at Broad Institute of MIT and Harvard, the team will utilize gastric cancer organoids – that are small, simplified, three-dimensional tumors or organs grown in a lab – in addition to other scientific methods to check medicines that deliver biologic therapies called ‘antibody drug conjugates’ with the goal of finding latest therapies for FGFR2 positive gastric cancer patients.

• The Phillip A. Sharp Innovation in Collaboration Award: Defining immunotherapeutic potential in genome instability-driven squamous cell carcinomas – This team will construct on currently funded SU2C research to discover latest therapeutic options for Fanconi anemia patients, who’re at a high risk of head and neck cancer and have few viable treatment options. Led by Agata Smogorzewska, M.D., Ph.D., professor at Rockefeller University, and Benjamin Greenbaum, Ph.D., director of computational immune-oncology at Memorial Sloan Kettering Cancer Center, the team will evaluate the likelihood that certain cancers – including head and neck cancer – will reply to immune-based therapies.

The 2023 SU2C Maverick Award is:

• AI for Targeting Undefined Molecular Subtypes of Head/Neck Cancer – This award will fund work to higher understand the subgroups of head and neck squamous cell carcinoma (HNSCC) with the goal of informing higher treatment strategies. Maverick Award winner Alexander Pearson, M.D., Ph.D., associate professor of drugs at University of Chicago, will utilize artificial intelligence to mix various forms of disease information – including DNA, digital images of head and neck cancer tumors, and other datasets – to provide a comprehensive representation of HNSCC.